Rethinking Neurodegenerative Disease Treatment: Target Multiple Pathological Proteins, Not Just One
Nearly all major neurodegenerative diseases – from Alzheimer’s to Parkinson’s – are defined and diagnosed by the presence of one of four proteins that have gone rogue: tau, amyloid-beta (Aβ), alpha-synuclein (α-syn), or TDP-43. As such, investigational drugs and studies aimed at preventing or slowing the disease often hone in on just one of these respective proteins. However, targeting multiple proteins—known as “proteinopathies”—at once may be the real key, according to a recent study published in Brain by Penn Medicine researchers.
ADCC IN THE NEWS
07/06/18Proteinopathies, the misfolded proteins responsible for neuron deaths, have a claim to fame when it comes to rare neurodegenerative diseases.
07/05/18As the saying goes, when life gives you lemons, you make lemonade. Meet a physicist turned copper artist who took up the craft after a devastating diagnosis.
06/25/18Money, medications, technology and transportation. Repeat these four words until you remember them. They’re the keys to making an important decision.
Penn Medicine's 7th Annual 5K for the IOA & The Memory Mile Walk
Sunday, September 23, 2018
8:00am | Penn Park
Help raise vital dollars for Alzheimer's and aging-related research and care at Penn's Institute on Aging (IOA)!
Learn More and Register Online More Events
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.